Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin vs Glibenclamide for Glucose Variability in T2DM
NCT02318693Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoint: Change From Baseline in Mean Amplitude of Glycemic Excursions at 13 days. Started Feb 2015; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02318693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318693.